

5-1-2017

Chronic myeloid leukemia after chemotherapy for adenocarcinoma of the rectum: A case report

Likhasit Sanglutong

Somchai Insiripong

Follow this and additional works at: <https://digital.car.chula.ac.th/clmjournal>



Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Sanglutong, Likhasit and Insiripong, Somchai (2017) "Chronic myeloid leukemia after chemotherapy for adenocarcinoma of the rectum: A case report," *Chulalongkorn Medical Journal*: Vol. 61: Iss. 3, Article 7. Available at: <https://digital.car.chula.ac.th/clmjournal/vol61/iss3/7>

This Clinical Report is brought to you for free and open access by the Chulalongkorn Journal Online (CUJO) at Chula Digital Collections. It has been accepted for inclusion in Chulalongkorn Medical Journal by an authorized editor of Chula Digital Collections. For more information, please contact ChulaDC@car.chula.ac.th.

Chronic myeloid leukemia after chemotherapy for adenocarcinoma of the rectum: A case report

Likhasit Sanglutong*

Somchai Insiripong*

Sanglutong L, Insiripong S. Chronic myeloid leukemia after chemotherapy for adenocarcinoma of the rectum: A case report. Chula Med J 2017 May – Jun; 61(3): 357 - 62

Chronic myeloid leukemia (CML) after chemotherapy for any primary malignancy has been occasionally reported. Herein we reported one definite case of CML who was diagnosed after the treatment of adenocarcinoma of the rectum. A 79-year-old Thai man was diagnosed with moderately differentiated adenocarcinoma of the rectum invading the urinary bladder. And he was treated with rectal resection and lymph nodes excision, followed by 5-fluoro-uracil and leucovorin therapy. He remained in complete remission for 1.5 years until he suddenly passed the hematochezia for one day and very high white blood cell and platelet counts without weight loss. The physical examination revealed no hepatosplenomegaly, no abdominal mass. The blood tests revealed: hemoglobin 10.6 g%, white blood cell 57,100/mm³, platelet 2,898,000/mm³, neutrophil 68 %, lymphocyte 6 %, basophil 20 %, band 1 %. The chromosome study from the blood was positive for 46,XY,t(9;22) (q34;q11.2)[20] but negative for JAK-2 V617F mutation. Serum Carcinoembryonic antigen (CEA) level was continually normal both before the surgery and through out the follow-up. His definite diagnosis was established as CML, the accelerated phase with the history of 5-FU chemotherapy for the adenocarcinoma of the rectum. He did not accept further investigations for detecting the local recurrence of the rectal adenocarcinoma and refused tyrosine kinase inhibitor therapy. He could survive one year after the diagnosis of CML without serious symptom while this study was being reported. So far it could not be concluded that the occurrence of CML after the chemotherapy of the rectum adenocarcinoma is just co-incidental or has any relationship.

Keywords: Chronic myeloid leukemia, adenocarcinoma of rectum.

Correspondence to: Insiripong S. Department of Medicine, Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, 30000.

Received for publication. January 26, 2017.

ลิขสิทธิ์ แสงสุทอง, สมชาย อินทศิริพงษ์. มะเร็งเม็ดเลือดขาวเรื้อรัง หลังการให้เคมีบำบัด
มะเร็งเยื่อบุลำไส้ตรง: รายงานผู้ป่วย 1 ราย. จุฬาลงกรณ์เวชสาร 2560 พ.ศ. -มิ.ย.;61(3):
357 - 62

มะเร็งเม็ดเลือดขาวเรื้อรัง (*chronic myeloid leukemia* หรือ CML) ที่เป็นตามหลังการได้รับยาเคมีบำบัดเพื่อรักษามะเร็งชนิดต่าง ๆ นั้น ยังพบบได้น้อยมาก ในรายงานนี้เป็นของผู้ป่วยมะเร็งเม็ดเลือดขาวเรื้อรัง ที่เป็นหลังจากผู้ป่วยได้รับยาเคมีบำบัดเพื่อรักษา adenocarcinoma ของลำไส้ตรง ผู้ป่วยเป็นชาย ไทย อายุ 79 ปี เคยได้รับการวินิจฉัยว่าเป็น moderately differentiated adenocarcinoma ของลำไส้ตรง ที่เริ่มแพร่กระจายเข้ากระเพาะปัสสาวะ และได้รับการรักษาด้วยการผ่าตัด rectal resection and lymph node excision และ ต่อด้วยยาเคมีบำบัดชนิด 5-fluoro-uracil และ leucovorin ผู้ป่วยอยู่ในสภาวะสงบตลอด 1 ปีครึ่ง จนวันที่ผู้ป่วยถ่ายเป็นเลือดสดกะทันหันในเวลา 1 วัน ร่วมกับการพบเม็ดเลือดขาว และ เกล็ดเลือดในเลือดสูงมาก โดยไม่มีน้ำหนัลด ตรวจร่างกายไม่พบว่ามีตับหรือม้ามโต ไม่พบก้อนในท้อง ตรวจเลือดพบว่าฮีโมโกลบิน 10.6 กรัม%, เม็ดเลือดขาว 57,100/มม³, เกล็ดเลือด 2,898,000/มม³, นิวโทรฟิล 68 %, ลิมโฟไซต์ L6 %, เบโซฟิล 20 %, band 1 % ตรวจโครโมโซมจากเลือดพบว่าให้ผลบวกต่อ 46,XY,t(9;22) (q34; q11.2) [20] แต่ไม่พบ JAK-2 V617F mutation ระดับ carcinoembryonic antigen (CEA) ในเลือดยังคงอยู่ในเกณฑ์ปกติตลอดนับตั้งแต่ก่อนผ่าตัด จนกระทั่งระหว่างการติดตามอาการให้การวินิจฉัยในที่สุดว่าเป็นมะเร็งเม็ดเลือดขาวเรื้อรังในระยะเร่งเร้า ตามหลังการให้ยาเคมีบำบัดสำหรับมะเร็ง adenocarcinoma ของเยื่อบุลำไส้ตรง ผู้ป่วยไม่ขอรับการตรวจเพิ่มเติมเพื่อหาการกลับเป็นซ้ำที่ตำแหน่งเดิมของโรคมะเร็ง adenocarcinoma ของลำไส้ตรง ไม่ขอรับการรักษาด้วยยากลุ่ม tyrosine kinase inhibitor อย่างไรก็ตาม ขณะที่เขียนรายงานนี้ผู้ป่วยก็ยังคงมีชีวิตรอดอีก 1 ปีโดยไม่มีอาการร้ายแรง จนปัจจุบันก็ยังสรุปไม่ได้ชัดเจนว่า CML ที่พบหลังจากที่ได้รับยาเคมีบำบัดสำหรับรักษา adenocarcinoma ของลำไส้ตรง เกิดขึ้นโดยบังเอิญ หรือว่ามีส่วนเกี่ยวข้องกัน

คำสำคัญ: มะเร็งเม็ดเลือดขาวเรื้อรัง, มะเร็งเยื่อบุลำไส้ตรง.

Chronic myeloid leukemia (CML) is one of the clonal myeloproliferative neoplasms (MPN) especially the white blood cell precursors. Therefore it is mainly characterized by the high peripheral white blood cell count with the young forms of all stages of the differentiation and the existence of the BCR-ABL translocation in most patients.⁽¹⁾ Almost all cases of CML occur spontaneously as *de novo* CML whereas the secondary CML following any solid tumor from various organs with or without chemotherapy is considered rare. It has been found as a case report in the patients with the esophageal carcinoma⁽²⁾, lymphoma^(3,4), breast carcinoma⁽⁵⁾ or thyroid carcinoma with radioactive iodine therapy.^(6,7) Likewise, only 4 cases of CML were occasionally reported after the diagnosis and treatment of adenocarcinoma of the colo-rectum. All of them were males and three of four cases were more than 60 years old⁽⁸⁻¹⁰⁾, whereas the rest was only 25.⁽¹¹⁾ And all were presumed to be due to the various regimens of chemotherapy resulting in treatment-related CML. The time interval between the diagnosis of the primary cancer and the treatment-related CML was 1 - 16 years.⁽⁹⁾ Likewise, the occurrence of adenocarcinoma of colon is either hardly found in cases with CML, viz., only two of 150 patients with CML, chronic phase who were treated with imatinib.⁽¹²⁾ Herein, we report a Thai man who emerged a definite CML after he was diagnosed as having pathologically proven adenocarcinoma of the rectum and the treatment with chemotherapy.

Case Report

A 79-year-old Thai man was referred to a hematologist because of a sudden passing of hematochezia for one day and high white blood cell

and platelet counts in the periphery, without fever, or weight loss.

One and a half years ago, he had passed the hematochezia for 1 month, and he was found to have a mass at the finger tip from the per rectum examination. The colonoscopy and the cystoscopy found a mass at the upper rectosigmoid colon invading into the wall of the urinary bladder. The microscopic pathology revealed moderately differentiated adenocarcinoma of the rectum. The rectal resection and lymph nodes excision with sigmoid colostomy were performed and one of three lymph nodes excised was found positive for cancer. He was treated with 6 courses of 5-fluoro-uracil 425 mg/m² + leucovorin 20 mg/m² as the adjuvant chemotherapy, no radiation. Nine months after chemotherapy, the ultrasonography of the abdomen was unremarkable while complete blood counts (CBC) was tested and found unremarkable every 3 months until the last one showed marked leukocytosis as above.

The follow-up physical examination revealed no hepatosplenomegaly, no abdominal mass.

The blood tests: hemoglobin (Hb) 10.6 g%, hematocrit (Hct) 33.9 %, White blood cell (WBC) 57,100/mm³, platelet 2,898,000/mm³, MCV 81.3 fL, RDW 19.0 %, neutrophil 68 %, lymphocyte 6 %, monocyte 1 %, eosinophil 4 %, basophil 20 %, band 1 %

The chromosome study from the blood showed positive for 46,XY,t(9;22)(q34;q11.2)[20] but negative for JAK-2 V617F mutation, carcinoembryonic antigen (CEA) 8.5 ng/mL (0 -15), normal liver and kidney function tests.

The ultrasonography of the abdomen showed no hepatosplenomegaly, no abdominal mass.

His definite diagnosed as established as CML, accelerated phase after the chemotherapy of adenocarcinoma of the rectum. However, the patient refused further investigations for detecting the local recurrence of rectal cancer and likewise the tyrosine kinase inhibitor therapy. He didnot attend the clinic again while this study was being reported, he was known still alive without any serious symptom one year after the diagnosis of CML by phone.

Discussion

The CML was definitely diagnosed based on the high WBC and the presence of BCR-ABL translocation and it was in the acceleration phase because of the high basophil count (20 %)⁽¹³⁾ while adenocarcinoma of the rectum was diagnosed based on tissue pathology, although CEA did not increase. Actually, the very high level of CEA is found in only 41.2 % of colorectal carcinoma.⁽¹⁴⁾

CML after chemotherapy or treatment-related CML is rare. Some authors propose that 5-FU may stimulate the dormant hematopoietic stem cells, especially CML⁽¹⁵⁾, which may be carcinogenic⁽⁹⁾ or chemotherapy may induce the translocation of the genes of the bone marrow stem cells.⁽¹⁶⁾

In the analysis of the incidence of second cancers among CML patients before the era of tyrosine kinase inhibitors, there are increased risks for many cancers such as the stomach (standardized incidence ratios or SIR = 2.8, 95% CI: 1.3, 5.1), skin (or SIR = 5.4, 95% CI: 3.2, 8.5), the urogenital tract (SIR = 1.6, 95% CI: 1.2, 2.2), and lymphoid leukemia (SIR = 5.5, 95% CI: 1.8, 12.9) in comparison with the general

population, no risks for the colorectal cancer or non-Hodgkin lymphoma.⁽¹⁷⁾

Both CML and the colorectal carcinoma have chromosomal aberrations. While BCR-ABL mutation is found in most cases of the former⁽¹⁸⁾, the genomic changes in some cases of the latter include the activation of proto-oncogenes (K-Ras) and the inactivation of at least 3 tumor suppression genes, namely, loss of APC (region 5q21), loss of p53 (region 17p13), and loss of heterozygosity for the long arm of chromosome 18 (18q LOH), others including the TGFBR and PIK3CA.⁽¹⁹⁾ However, the relationship between these two sets of the chromosomal aberrations from both groups has not been mentioned. BCR-ABL translocation was found in our case.

So far it cannot be simply concluded that the emergence of CML after colon carcinoma and vice versa suggesting their truly causal relationship or just a co-incidence.⁽²⁰⁾

Conclusion

A 79-year-old Thai man was definitely diagnosed as CML, 1.5 years after 5-FU therapy for rectal cancer. However, the relationship between CML and the rectal cancer with or without chemotherapy could not be simply concluded.

References

1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. *Am J Hematol* 2016;91:252-65.
2. Namakura H, Inokuchi K, Hanawa H, Yamaguchi H, Tamura H, Tajika K, et al. A case of Chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for

- esophageal carcinoma. *Ann Hematol* 2000; 79:396-401.
3. Alsop S, Sanger WG, Elenitoba-Johnson KS, Lim MS. Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma. *Hum Pathol* 2007;38: 1576-80.
 4. Zahra K, Ben Fredj W, Ben Youssef Y, Zaghouni H, Chebchoub I, Zaier M, et al. Chronic myeloid leukemia as a secondary malignancy after lymphoma in a child. A case report and review of the literature. *Onkologie* 2012; 35:690-3.
 5. Ocakç1 S, Görümlü G, Sahin F, Özsan N, Zekioglu O, Uslu R, et al. Occurrence of chronic myeloid leukemia in two breast cancer survivors after 4 years. *Ege J Med* 2011;50:141-4.
 6. Walgraeve D, Verhoef G, Stul M, Cassiman JJ, Mecucci C, Van den BH, et al. Chronic myelogenous leukemia after treatment with I131 for thyroid carcinoma. Report of a case and review of the literature. *Cancer Genet Cytogenet* 1991;55:217-24.
 7. Wang KL, Lin LY, Chen PM, Lin HD. Chronic myeloid leukemia after treatment with I131 for thyroid carcinoma. *J Chin Med Assoc* 2005;8:230-3.
 8. Gokel Y, Paydas S. Chronic myeloid leukemia in a patient with colon adenocarcinoma. *Haematologia (Budap)* 2002;32:501-3.
 9. Kadikoylu G, Yavasoglu I, Barutca S, Meydan N, Bolaman Z. Chronic myeloid leukemia following the treatment of rectal adenocarcinoma. *Med Oncol* 2008;25:467-70.
 10. Buxhofer-Ausch V, Hinterberger-Fischer M, Hinterberger W. Bcr-abl positive blast crisis of CML emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan. *Eur J Haematol* 2006;76:447-8.
 11. Vakili-Sadeghi M, Omranpour M. Chronic myeloid leukemia following colon cancer treatment: A case report and literature review. *Caspian J Intern Med* 2013;4:739-42.
 12. Frustaci A, Breccia M, Cannella L, Stefanizzi C, Alimena G. Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: report of two cases and review of the literature. *Leuk Res* 2009; 33:200 -1.
 13. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the WHO proposal. *Cancer* 2006;106:1306-15.
 14. Filiz AI, Sucullu I, Kurt Y, Karakas DO, Gulec B, Akin ML. Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients-Is it important? *Clinics (Sao Paolo)* 2009;64:287-94.
 15. Peng C, Chen Y, Shan Y, Zhang H, Guo Z, Li D, et al. LSK derived Isk- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells. *PLoS ONE* 2012;7): e38614
 16. Bauduer F, Ducout L, Dastugue N, Marolleau JP. Chronic myeloid leukemia as a second neoplasm after anti-cancer radiotherapy: a report of three cases and a brief review of the literature. *Leuk Lymphoma* 2002;43:

- 1057-60.
17. Rebora P, Czene K, Antolini L, Passerini CG, Reilly M, Valsecchi MG. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. *Am J Epidemiol* 2010;172:1028-33.
18. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous-leukaemia. *Nat Rev Cancer* 2005;5:172-83.
19. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. *Gastrointest Cancer Res* 2012;5:19 -27.
20. Kanellopoulou T, Kontopidou FN, Skondra M, Pliarchopoulou K, Pectasides D. Chronic myeloid leukemia and colon cancer: A causal relationship or coincidence? *Ann Gastroenterol* 2011;24:140-1.